difficulty in initiating sleep; (2) difficulty in maintaining sleep; or (3) waking up too early. A fourth characteristic, nonrestorative or poor-quality sleep, has frequently been included in the definition, although there is controversy as to whether individuals with this complaint share similar pathophysiologic mechanisms with the others." 25 Another significant problem with studies of the impact of insomnia is that sleep complaints frequently coexist in individuals with medical and psychologic problems that could be the actual or primary cause of adverse associations of insomnia. In fact, the National Institutes of Health consensus conference noted, "Insomnia usually appears in the presence of at least one other disorder. Particularly common comorbidities are major depression, generalized anxiety, substance abuse, attention deficit/hyperactivity in children, dementia, and a variety of physical problems. The research diagnostic criteria for insomnia recently developed by the American Academy of Sleep Medicine indeed share many of the criteria of major depressive disorder. Studies to explain these overlaps require determining how often insomnia precedes the disorders with which it is associated and whether it continues to exist if the other disorders go into remission."
Thus, prospective studies that carefully control for comorbidities are needed to assess the impact of sleep complaints. The purpose of this study was to use well-established cohort data to investigate whether specific insomnia complaints, combinations of complaints, or use of hypnotics increased the risk of hypertension or cardiovascular disease.
METHODS

Participants
The ARIC study is a prospective study of the natural history and etiology of atherosclerotic disease and of cardiovascular disease event rates and is described in detail elsewhere. 26 The study cohort was as a probability sample of men and women aged 44 to 64 years from 4 US communities: Forsyth County, NC (WinstonSalem); Jackson, MS; Washington County, MD. (Hagerstown); and suburbs of Minneapolis, MN. Baseline examinations, tests, and interviews were conducted during 1987 to 1989, and participants subsequently were contacted on an annual basis. Survivors were invited to take part in 3 follow-up data collections at intervals of approximately 3 years. In this analysis, we used data from the second visit as the baseline for establishment of behavioral and sociodemographic variables and used survival at follow-up (mean, 6.3 + 1.1 years) as a dependent variable. In order to assess whether sleep complaints were a risk factor for development of hypertension or cardiovascular disease, we studied only those subjects who were free of hypertension or cardiovascular disease at baseline (ARIC visit 2). The study objectives, design, sampling scheme, and cohort examination procedures have been described. 26 
Variable Measurement and Definitions
Most measurements reported here were collected at the second ARIC examination (1990) (1991) (1992) . Three sleep complaints were available as part of the Masstricht questionnaire:
"Do you often have trouble falling asleep?" (difficulty falling asleep); "Do you wake up repeatedly during the night?" (sleep continuity disturbance); and "Do you ever wake up with a feeling of exhaustion and fatigue?" (nonrestorative sleep). 27 Age was stratified into 5 categories: 45 to 49, 50 to 54, 55 to 59, 60 to 64, and 65 to 69. Race was classified, based on selfreport, as black or white. Education level was categorized as less than high school, completion of high school, or more than high school. Body mass index was calculated as weight divided by height squared (kg/m 2 ) and divided into 4 categories: < 20, 20 to 24, 25 to 29, and > 30. We screened for depression with the Maastricht Questionnaire, 27 which was developed to assess vital exhaustion. This is a 21-item questionnaire that correlates with depression as assessed by the Hospital Anxiety and Depression Scale. 28 We defined as depressed the upper quartile of participants who gave a positive response to 4 or more of the following 13 questions: (1) Would you want to be dead at times? (2) Do you feel dejected? (3) Have you experienced a feeling of hopelessness recently? (4) Do you believe that you have come to a dead end? (5) Do you have the feeling these days that you just do not have what it takes anymore? (6) Do you feel like crying sometimes? (7) Do you lately feel more listless than before? (8) Do you feel that your body is like a battery that is losing its power? (9) Do you have the feeling that you cannot cope with everyday problems as well as you used to? (10) Do you have the feeling that you have not been accomplishing much lately? (11) Do you feel weak all over? (12) Do little things irritate you more than they used to? (13) Does it take you more time to grasp a difficult problem than it did a year ago? Using a modification of the criteria developed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), subjects were classified according to their GOLD stages of chronic obstructive pulmonary disease (COPD): GOLD stage 3 or 4 (FEV 1 /FVC < 0.70 and FEV 1 < 50% predicted), GOLD stage 2 (FEV 1 /FVC < 0.70 and FEV 1 ≥ 50 to < 80% predicted), GOLD Stage 1 (FEV 1 /FVC < 0.70 and FEV 1 ≥ 80%), restricted (FEV 1 /FVC ≥ 0.70 and FVC < 80% predicted), GOLD stage 0 (presence of respiratory symptoms in the absence of any lung function abnormality), and no lung disease. 29 Respondents with positive responses to "Have you ever smoked cigarettes?" and "Do you now smoke cigarettes?" were classified as "ever smokers" and "current smokers," respectively. Diabetes was defined as a fasting glucose of > 126 mg/dL or a self-reported history of or treatment for diabetes.
Systolic and diastolic fifth-phase blood pressures were measured 3 times using a random zero sphygmomanometer in the right arm in seated participants. The mean of the last 2 measurements was used in analyses. Hypertension (both at the visit 2 and visit 4 assessment) was defined as a systolic blood pressure of greater than 160 mm Hg or diastolic greater than 95 or the use of antihypertensives. Cardiovascular disease (at both the visit 2 and the visit 4 assessment) was defined as physician-diagnosed fatal or nonfatal myocardial infarction, suspected or probable myocardial infarction, or other primary cardiac event.
We performed analyses using various insomnia complaints and combinations of complaints, including (1) a complaint of difficulty falling asleep or staying asleep; (2) a complaint of difficulty falling asleep AND staying asleep, plus a complaint of nonrestorative sleep; (3) a complaint of difficulty falling asleep OR staying asleep, plus a complaint of nonrestorative sleep.
Analysis
All analyses were conducted with SAS version 8.2 (SAS Institute, Cary, NC), SUDAAN version 8.0 (RTI, Research Triangle Park, NC) and SPSS version 10 (SPSS Inc, Chicago, IL, USA). Our primary outcomes of interest were development of new cardiovascular disease or hypertension, and the main predictors of interest in our analysis were sleep complaints, singly and in various combinations.
We also performed multinomial logistic regression analysis of the factors predicting incident cardiovascular disease (among people who were free of cardiovascular disease at visit 2) and incident hypertension (among people free of hypertension at visit 2) and people who were not available for follow-up in both cohorts. Models were adjusted for age, sex, education level, BMI, depression, lung function status, smoking status, and diabetes,
RESULTS
Tables 1 and 2 demonstrate the incidence of hypertension and cardiovascular disease, respectively, in those subjects who were free of the outcome of interest at baseline (visit 2). These tables also include descriptors and percentages of participants enrolled in the study who were not available for follow-up. Individuals who were not available for follow-up were different from those from whom data were collected at the 6-year follow-up.
Overall, 20% of the 8757 who were free of hypertension at baseline developed hypertension over the follow-up period. Similarly, 4.6% of the 11,863 individuals who were free of cardiovascular disease at baseline developed cardiovascular disease over the follow-up period.
With regard to incident hypertension (Table 3) , those who endorsed a symptom of either difficulty falling asleep or sleep continuity disturbance had a slightly increased risk (odds ratio [OR] 1.2, confidence interval [CI] 1.03-1.3) of developing hypertension even after controlling for confounders, but no combination of sleep complaints predicted incident hypertension.
With regard to the development of cardiovascular disease (Table 4), the combination of all 3 sleep complaints (difficulty falling asleep, sleep continuity disturbance, and nonrestorative sleep) was associated with a slightly increased risk incident cardiovascular disease (OR 1.5, CI 1.1-2.0). The combination of difficulty falling asleep or sleep continuity disturbance plus nonrestorative sleep did not predict an increased likelihood of development of either hypertension or cardiovascular disease.
DISCUSSION
Perhaps the most important finding of this analysis is that the definition of insomnia affects its impact. The combination of difficulty falling asleep or difficulty staying asleep plus nonrestorative sleep was not associated with increased risk of hypertension or of cardiovascular disease. However, we found a modest and inconsistent effect of sleep complaints on hypertension and cardiovascular disease; those individuals who reported all 3 sleep complaints at baseline had a slightly increased risk of cardiovascular disease (but not hypertension) at follow-up, and those who reported difficulty falling asleep or sleep continuity disturbance had a slightly increased risk of hypertension (but not cardiovascular disease) at follow-up. This inconsistency in morbidities asInsomnia, Hypertension, and Cardiovascular Disease sociated with insomnia complaints highlights a major difficulty in assessing the impact of insomnia; a valid reliable definition of insomnia remains elusive, 30 and its component symptoms and combinations of symptoms are associated with variable outcomes. Further, whether a given constellation of symptoms represents a variant of insomnia or a marker of a more serious condition is not clear. Even the minor risks associated with insomnia complaints that we found in this study might be due to the comorbidities rather than to the insomnia symptoms. In particular, it is possible that hypertension and cardiovascular related to insomnia complaints may be due to underlying sleep apnea, which is frequently associated with insomnia. 31 Indeed, we cannot be certain that the associations that we found were not contaminated by undiagnosed sleep-disordered breathing. However, we did control for body mass index, an indirect marker of sleep apnea risk, in our analyses.
Short sleep duration is strongly linked to morbidity and mortality, 13, [15] [16] [17] [18] [19] [20] whereas (as the current study indicates) the association between sleep complaints (insomnia) and adverse outcomes B Phillips, DM Mannino 33 Blurring the lines between insomnia and short sleep may contribute to our inability to ascertain the impact of insomnia. Short sleep duration (which may overlap with insomnia) is a different entity with a different impact than complaints about the ina.bility to sleep when the opportunity exits to do so.
By necessity, we assessed insomnia complaints in this secondary analysis using the data at hand; this study was not designed to assess the relationship between sleep complaints and cardiovascular outcomes per se. Use of instruments specifically designed to capture insomnia would have been preferable, but we believe that there is some value in secondary analyses of large datasets such as the ARIC cohort.
The current study has several strengths. First, the longitudinal nature of this study allows for prospective investigation of the likelihood that sleep complaints predict adverse cardiovascular outcomes. Another strength is the ability to apply several of the sleep complaints that make up the entity of insomnia in order to assess the impact of varying definitions of insomnia. Finally, the ARIC population includes more than 13,000 well-characterized individuals, allowing for control for multiple confounders and individual characteristics. Because depression overlaps with insomnia to a great extent, 25 it is especially important to be able to control for this variable, as we were able to do. In a prospective evaluation of the relationship of a single insomnia complaint (difficulty falling asleep) to hypertension, Japanese investigators reported a positive association; although they were able to control for many important variables, they did not control for depression. 34 A 1999 review of studies assessing the relationship between insomnia complaints and coronary heart disease found 10 studies that suggested an increased risk of development of coronary events in those with difficulty falling asleep, 35 but these older papers did not consistently include and control for the multitude of variables that are relevant to this issue.
The modest and inconsistent associations that we found between sleep complaints and incident cardiovascular disease and hypertension suggest that insomnia is not a robust contributor to adverse cardiovascular events.
